High fluorescence quantum yields, high singlet oxygen quantum yields and intense absorptions in the phototherapeutic window are fundamental properties for compounds intended for fluorescence diagnosis and photodynamic therapy. We report on photostable chlorins that combine these properties. The fluorinated tetraphenylchlorin FCMet has Φ_F = 0.396 and Φ_Δ = 0.58 ± 0.07, whereas F₂CMet has Φ_F = 0.360 and Φ_Δ = 0.54 ± 0.05, and both have molar absorption coefficients larger than 30 000 M⁻¹ cm⁻¹ above 650 nm. These dual functional agents use nearly all the energy absorbed to perform the desired functions and are appropriate for theranostics applications.

We assessed the tolerability and safety in rodents of a single intravenous (i.v.) dose of redaporfin, a novel photosensitizer for Photodynamic Therapy (PDT) of cancer. Two approaches were used to evaluate acute toxicity: (i) a dose escalation study in BALB/c mice to evaluate the maximum tolerated dose of redaporfin; and (ii) a safety toxicology study in Wistar rats, of a single dose of redaporfin, with or without illumination, to evaluate possible signs of systemic toxicity. Redaporfin formulation was well tolerated by mice, with no signs of adverse reactions up to 75 mg/kg. In rats, there were no relevant changes, except for a significant, but transient, increase in the blood serum markers for hepatic function and muscle integrity, and also on neutrophil counts, observed after the application of light. The overall results showed that redaporfin-PDT is very well tolerated. No abnormalities were observed, including reactions at the injection site or skin phototoxicity, although the animals were maintained in normal indoor lighting. Redaporfin also showed a high efficacy in the treatment of male BALB/c mice with subcutaneously implanted colon (CT26) tumours. Vascular-PDT with 1.5 mg/kg redaporfin and a light dose of 74 J/cm² led to the complete tumour regression in 83% of the mice.